Unity Biotechnology Inc (STU:9U90)
€ 1.308 -0.008 (-0.61%) Market Cap: 22.57 Mil Enterprise Value: 9.93 Mil PE Ratio: 0 PB Ratio: 0.98 GF Score: 30/100

UNITY Biotechnology Inc To Discuss Lead Program UBX1325 Call Transcript

Aug 12, 2022 / 12:00PM GMT
Release Date Price: €17.62 (+111.47%)
Operator

Good morning, and welcome to the Unity Biotechnology Investor Call. (Operator Instructions)

Today's call will be recorded, and a replay will be available on the Unity Biotechnology website.

At this time, I would now like to turn the call over to your host, Lynne Sullivan, CFO of Unity Biotechnology. Please go ahead, Lynne

Lynne Marie Sullivan
Unity Biotechnology, Inc. - CFO & Head of Corporate Development

Good morning. Thank you for joining the Unity Biotechnology Conference Call to discuss the 12-week and 18-week results from our BEHOLD study, a Phase II study of UBX1325 in patients with diabetic macular edema. I'm Lynne Sullivan, Chief Financial Officer of Unity Biotechnology. With me on today's call is renowned retinal specialists, Robert Bhisitkul, Professor of Ophthalmology and Director Retina Fellowship at University of California, San Francisco; Anirvan Ghosh, the CEO of Unity Biotechnology; and Jamie Dananberg, the Chief Medical Officer of Unity Biotechnology.

On today's call, Anirvan will begin with an overview of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot